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ABSTRACT 
CD177 is a neutrophil-specific receptor 
presenting proteinase 3 (PR3) autoantigen on the 
neutrophil surface. CD177 expression is restricted 
to a neutrophil subset resulting in 
CD177pos/mPR3high and CD177neg/mPR3low 
populations. The size of the CD177pos/mPR3high 
subset has implications for anti-neutrophil 
cytoplasmic autoantibody (ANCA)-associated 
autoimmune vasculitis (AAV) where patients 
harbor PR3-specific ANCA that activate 
neutrophils. We generated high affinity anti-
CD177 monoclonal antibodies, some of which 
interfered with PR3 binding to CD177 (PR3 
“blockers”) as determined by surface plasmon 
resonance spectroscopy, and used them to test the 
effect of competing PR3 from the surface of 
CD177pos neutrophils. Because intact anti-CD177 
antibodies also caused neutrophil activation, we 
prepared non-activating Fab fragments of a PR3 
blocker and non-blocker that bound specifically 
to CD177pos neutrophils by flow cytometry. We 
observed that Fab blocker clone 40, but not non-
blocker clone 80, dose-dependently reduced anti-
PR3 antibody binding to CD177pos neutrophils. 
Importantly, preincubation with clone 40 
significantly reduced respiratory burst in primed 
neutrophils challenged either with monoclonal 
antibodies to PR3 or PR3-ANCA IgG from AAV 
patients. After separating the two CD177/mPR3 
neutrophil subsets from individual donors by 
magnetic sorting, we found that PR3-ANCA 
provoked significantly more superoxide 
production in CD177pos/mPR3high than in 
CD177neg/mPR3low neutrophils, and that anti-
CD177 Fab clone 40 reduced the superoxide 
production of CD177pos cells to the level of the 
CD177neg cells. Our data demonstrate the 
importance of the CD177:PR3 membrane 
complex in maintaining a high ANCA epitope 
density and thereby underscore the contribution 
of CD177 to the severity of PR3-ANCA diseases. 
 
 
As the most abundant leukocytes, neutrophil 
granulocytes represent one of the first lines of 
defense against infectious agents and are 
therefore a pillar of the innate immune system. 
Among their most potent defense mechanisms is 
degranulation, whereby stores of cytotoxic 
species housed in several types of intracellular, 
membrane bound compartments called granules, 
are moved to the cell surface and released into the 
extracellular environment as a response to 
pathogen detection (1). This toxic cocktail is 
designed to kill foreign cells in the vicinity of the 
neutrophil. Given that healthy cells are also 
negatively affected, degranulation is a highly 
regulated process (though not yet fully 
understood) (2).  The serine protease proteinase 3 
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(PR3) is found in large abundance in human 
neutrophils  (3). It is a major component of 
neutrophil azurophilic granules but is 
interestingly also detectable on the outer surface 
of the neutrophil plasma membrane. In most 
individuals, two distinct neutrophil populations 
can be identified based on the amount of 
membrane bound PR3 (mPR3) they harbor – one 
with low amounts of mPR3 (mPR3low) and 
another with orders of magnitude more detectable 
mPR3 (mPR3high) (4). The mPR3high population is 
further distinguished by the presence of a 
selectively expressed membrane receptor called 
CD177 (5,6). CD177 is a GPI-anchored protein 
exclusively expressed in a subset of neutrophils 
and forms a high affinity complex with PR3. It 
thus accounts for the increased mPR3 levels that 
are detectable on the mPR3high subset (7). The 
proportion of CD177pos/mPR3high vs 
CD177neg/mPR3low neutrophils in a given 
individual is genetically determined and remains 
constant throughout life (8-10). Although the 
function of CD177 is still unclear, several studies 
have identified a correlation between a large 
CD177pos/mPR3high neutrophil population and the 
occurrence and progression of a group of 
incurable autoimmune diseases called ANCA 
(anti-neutrophil cytoplasmic antibody) 
vasculitides (8,11-14). In these disorders, 
autoantibodies directed against PR3 stimulate 
activation of neutrophils, ultimately resulting in 
degranulation. The resulting release of cytotoxic 
enzymes and peptides – circumventing the 
normally strictly controlled degranulation process 
- causes considerable systemic damage to healthy 
tissue and is the hallmark of these conditions. It 
has been shown that, although all neutrophils are 
activated upon exposure to PR3-ANCA, 
CD177pos/mPR3high neutrophils react more 
strongly to autoantibody binding, as measured by 
the generation of superoxide, an early indicator of 
the activation process (referred to as ‘oxidative 
burst’), and increased phosphorylation of Akt 
kinase (15). AAV patients with large 
CD177pos/mPR3high populations are more prone to 
relapse and show poorer clinical outcomes than 
those with smaller CD177pos/mPR3high 
populations (11-13). 
The mechanism by which PR3-ANCA activate 
neutrophils is not known. Since all neutrophils 
display mPR3 and are affected by PR3-ANCA, 
the presence of PR3 seems critical for the process. 
In the case of CD177pos/mPR3high neutrophils, 
which are more strongly affected by the binding 
of PR3-ANCA, the questions arise whether and 
how CD177 itself may contribute to ANCA-
stimulated neutrophil activation. Although 
CD177 does not cross the plasma membrane, it 
could interact with other species that do and in 
this way enhance the sensitivity of 
CD177pos/mPR3high neutrophils to the effects of 
PR3-ANCA.  
We sought to directly test the contribution of 
CD177 to PR3-ANCA-stimulated neutrophil 
activation. To this end, we generated a series of 
anti-CD177 antibodies, some of which bound to 
the CD177:PR3 complex and some of which 
blocked the binding of PR3. We used Fab 
fragments derived from the latter to selectively 
disrupt CD177:PR3 complexes on 
CD177pos/mPR3high neutrophils. We then tested 
the effect of this treatment on PR3-ANCA 
induced activation using both mixed and sorted 
neutrophil populations. We show that removing 
CD177 bound PR3 reduces the sensitivity of 
mixed neutrophil pools to PR3-ANCA treatment. 
When we tested separated CD177neg/mPR3low and 
CD177pos/mPR3high populations, we found that 
while Fab treatment had no effect on PR3-ANCA-
induced respiratory burst of CD177neg/mPR3low 
neutrophils, the anti-CD177 Fabs reduced the 
response of the CD177pos/mPR3high population to 
that of the CD177neg/mPR3low population. Thus, 
the excess mPR3 on CD177pos/mPR3high 
neutrophils appears to account for their enhanced 
sensitivity to PR3-ANCA. The presence of 
CD177 enables a higher density of PR3 epitopes 
that result in a stronger activation effect in 




Screening of anti-CD177 monoclonal antibodies 
identifies binders that block the CD177:PR3 
interaction 
We used recombinant CD177 (7) for the 
generation of mouse monoclonal antibodies 
against CD177. 10 of the resulting hybridoma 
products were assessed by surface plasmon 
resonance (SPR) spectroscopy to determine their 
binding affinities for CD177. All 10 IgGs bound 
CD177 with high affinity, ranging from 0.14 to 
11.9 x 10-9 M (Table 1). We attempted to 
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determine the ability of each IgG to block the 
binding of PR3 to CD177 by competition ELISA 
using an anti-PR3 antibody but were unable to 
optimize the assay to produce unambiguous 
results. We therefore devised a direct assay using 
SPR as depicted in Fig. 1. We immobilized each 
anti-CD177 IgG to the sensor chip and subjected 
them to two back-to-back ligand flows: the first 
ligand sample contained only CD177, which was 
allowed to flow over the immobilized IgGs until 
the resonance units (RUs) indicated near 
saturation of all binding sites (Figure 1A, B); the 
second ligand sample containing CD177:PR3 
complexes was then injected and the resulting 
effect on the RUs observed. Two possible RU 
responses could be expected. If the IgG in 
question does not interfere with the PR3 
interaction with CD177 (i.e. the IgG was a non-
blocker), then CD177:PR3 complexes could be 
exchanged for CD177 in the IgG binding sites, 
leading to a second pronounced increase in the 
RUs as the extra mass from PR3 was added to 
each binding interaction (Fig. 1B). Conversely, if 
the IgG does prevent interaction of PR3 with 
CD177 (i.e. the IgG is a blocker) then no further 
RU increase would be possible, but rather a 
decrease in RUs during flow of the complex, since 
bound CD177 will be lost from the immobilized 
IgG and there is insufficient free CD177 in the 
complex mixture to take its place. To minimize 
the concentration of free CD177 in the complex 
sample, the concentration used was 10-fold higher 
than the PR3 binding affinity, as measured also by 
SPR ((7), Fig. 1B). Using this assay, we 
unambiguously identified three PR3 blockers 
among the tested IgGs (Fig. 1C, clones 7, 40 and 
72), while the remainder were non-blockers 
(Table 1).  
 
PR3 blocker and non-blocker IgGs and their 
corresponding Fab fragments bind to CD177pos 
neutrophils, but only IgGs are activating 
We next verified that our anti-CD177 monoclonal 
antibodies could bind to intact human CD177pos 
neutrophils. Total neutrophil pools isolated from 
freshly donated blood samples were incubated 
with purified anti-CD177 IgG and subjected to 
FACS analysis. Binding was confirmed in all 
cases (data not shown). 
We also tested purified Fab fragments derived 
from each IgG by papain digestion and, again, 
confirmed binding of each to CD177pos 
neutrophils by FACS staining (Fig. 2A).  
Next, neutrophils were preincubated with our 
anti-CD177 IgGs and/or Fab fragments to test if 
PR3 blockers (clones 7, 40, and 72) interfered 
with subsequent anti-PR3 IgG binding (Fig. 2B). 
In contrast to PR3 non-blockers, the PR3 blockers 
reduced the anti-PR3 staining signal in the 
CD177pos neutrophil subset. 
Multivalent PR3 binders - like PR3-ANCA –
strongly activate neutrophils, but monovalent 
binders – like Fab fragments – do not. We 
therefore tested whether our CD177 binders also 
produced this response. We incubated isolated 
primed neutrophils with either anti-CD177 IgG or 
their corresponding Fabs and then determined to 
what extent they initiated oxidative burst by 
measuring the production of superoxide in the 
resulting aliquots. Though to differing extents, in 
all cases the multivalent anti-CD177 IgG 
provoked respiratory burst in mixed neutrophil 
pools (Fig. 2C). Their corresponding monovalent 
Fabs, however, showed no significant stimulatory 
effect, with most of the resulting superoxide 
concentrations comparable to the negative control 
value. These effects also showed no obvious 
correlation with either the blocking or non-
blocking properties of the individual binders or 
their relative affinities to CD177. For all further 
experiments with neutrophils, we chose to 
proceed with the IgG blocker clone 40 (Kd = 3.1 
x 10-9 M) and the non-blocker clone 80 (Kd = 2.3 
x 10-9 M) since both binders have a CD177 
affinity similar to that of PR3 (Kd = 4.1 x 10-9 M). 
 
A PR3 blocking Fab reduces anti-PR3 IgG 
stimulated oxidative burst in mixed 
(CD177pos/mPR3high / CD177neg/mPR3low) 
neutrophil populations 
We next tested whether preincubation of mixed 
population neutrophils with blocker Fab clone 40 
had any effect on the stimulation of superoxide 
production by anti-PR3 IgG. We first incubated 
unsorted neutrophils with a saturating amount (20 
g/ml) of either blocker clone 40 or non-blocker 
clone 80 and, after washing, activated the 
neutrophils by addition of a monoclonal anti-PR3 
antibody. The subsequent superoxide 
measurements showed that the anti-PR3 
monoclonal IgG strongly stimulated the 
neutrophil pool in all cases, as opposed to 
treatment with an isotype IgG that provoked only 
.CC-BY-NC-ND 4.0 International licenseavailable under a
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprint (whichthis version posted May 17, 2021. ; https://doi.org/10.1101/2021.05.17.444335doi: bioRxiv preprint 
Reducing surface PR3 reduces PR3-ANCA induced degranulation 
 
 4 
a background response (Fig. 3A). While the 
degree of superoxide generation in the presence 
of non-blocker clone 80 was not significantly 
different than that measured in the absence of Fab 
or the presence of a non-CD177 binding control 
Fab, the pool containing blocker clone 40 showed 
a clearly weaker stimulation and correspondingly 
less superoxide production, implying that the PR3 
blocking effect of clone 40 protects CD177pos 
neutrophils from activation by anti-PR3 IgG. 
FACS staining performed in parallel showed that 
pretreatment with blocker clone 40 significantly 
reduced anti-PR3 antibody binding to the 
CD177pos neutrophil subset, whereas non-blocker 
and control Fab showed no reduction in mPR3 
expression (Fig. 3A, B).  
 
To verify that the blocker clone 40 Fab was 
displacing CD177 bound PR3 from the CD177pos 
neutrophils, we incubated unsorted neutrophils 
with increasing concentrations of clone 40 Fab 
and monitored changes in detectable mPR3 by 
FACS. In the absence of Fab, the peaks 
corresponding to the CD177neg/mPR3low and 
CD177pos/mPR3high populations were widely 
separated; upon addition of the clone 40 Fab, the 
separation between the peaks (stained for PR3) 
decreased dose-dependently until they merged, 
with very little difference distinguishable between 
them at the highest Fab concentration tested (Fig. 
3C). This observation confirmed that the blocker 
Fab 40 not only prevented PR3 binding to CD177 
in SPR but also on the surfaces of living 
neutrophils. We then repeated our activation 
experiment with PR3-ANCA obtained from AAV 
patient serum. As in the previous experiment with 
an anti-PR3 monoclonal IgG, only preincubation 
with blocker Fab 40 had a negative influence on 
the stimulation of superoxide production by PR3-
ANCA (Fig. 3D).  
 
The effects on neutrophil activation 
demonstrated by Fab blocker clone 40 are 
restricted to the CD177pos/PR3high neutrophil 
population 
Preincubation of unsorted neutrophils with the 
PR3 blocking clone 40 Fab not only displaced 
PR3 from the CD177pos population, but also 
effected a clear reduction in the amount of 
superoxide produced as a result of stimulation 
with either monoclonal anti-PR3 IgG or PR3-
ANCA IgG isolated from AAV patient serum. In 
order to more precisely define the effect of 
blocker clone 40, we repeated the PR3-ANCA 
stimulation experiments with sorted neutrophils. 
We used magnetic cell sorting with our isolated 
neutrophils to produce pure CD177neg/mPR3low 
and CD177pos/mPR3high preparations (Fig. 4A) 
and tested them separately by preincubation with 
20 g/ml blocker clone 40 Fab before washing 
and addition of the stimulatory PR3-ANCA. As 
previously shown (15), both pure populations 
were activated by the addition of PR3-ANCA, 
with the CD177pos/mPR3high population producing 
nearly twice as much superoxide as the 
CD177neg/mPR3low population (Fig. 4B). 
Preincubation with non-blocker clone 80 showed 
no effect on superoxide production; the values for 
both populations in the presence of this Fab were 
identical to those either without added Fab or 
preincubated with a control Fab. Preincubation 
with blocker clone 40 showed no measurable 
effect on superoxide production by stimulated 
CD177neg/mPR3low neutrophils but a substantial 
effect with CD177pos/mPR3high neutrophils. The 
presence of clone 40 completely eliminated the 
difference in superoxide production between the 
two pure neutrophil populations.  
 
Discussion 
PR3 is a member of a family of neutrophil serine 
proteases important in inflammation and is known 
to process extracellular matrix proteins (3), cell 
surface receptors (16,17), cytokines (18,19) and 
intracellular effectors including kinase inhibitors 
(20), cytoskeletal proteins (21),  and annexin (22). 
As a major component of azurophilic granules, it 
is also released in abundance from neutrophils 
during degranulation. Although it is a soluble 
protein, it is detectable on the extracellular 
surface of all neutrophils and PR3 isolated from 
neutrophils readily adheres to the membranes of 
non-myeloid cells as well (7). PR3 possesses a 
patch of hydrophobic residues on its surface that 
have been suggested to be responsible for its 
interaction with membranes (23), though 
definitive proof for this supposition has yet to be 
reported. To date, the only confirmed (non-
substrate) interaction partner for PR3 is CD177, a 
GPI anchored protein with no clearly defined 
function. Due to its high affinity complex with 
PR3, CD177 is responsible for the abundant 
mPR3 occurring in neutrophils expressing it. As 
the target of autoantibodies, mPR3 is a central 
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player in ANCA vasculitis that, in an as yet 
unknown manner, facilitates autoantibody 
induced neutrophil activation leading ultimately 
to degranulation - a process normally requiring 
multiple, receptor initiated, signaling cascades (2). 
An outstanding question here is exactly how 
molecules that do not obviously function as 
receptor ligands and do not themselves cross the 
plasma membrane can nevertheless activate the 
intracellular signaling pathways necessary for the 
activation process. The fact that CD177pos 
neutrophils react more strongly in this regard than 
CD177neg neutrophils could be an indication that 
CD177 – though not recognized by PR3-ANCA – 
has, like PR3, a role in facilitating ANCA-
initiated activation, beyond serving as a platform 
for additional ANCA epitopes due to 
complexation with PR3. The experiments 
presented here address this possibility directly by 
blocking CD177:PR3 complex formation in situ 
and probing the effect of this epitope removal on 
the ANCA induced activation response. The clear 
result was that once the bulk of the CD177 bound 
PR3 was titrated away from the neutrophil surface, 
the ANCA sensitivity of the CD177pos population 
was fully reduced to that of the CD177neg 
population. ANCA addition still elicited a 
respiratory burst from these neutrophils, but this 
via the remaining directly membrane-bound 
mPR3 that exists in both populations. These 
results – along with the fact that CD177neg 
neutrophils are also sensitive to PR3-ANCA - 
make clear that CD177 is not directly required for 
the ANCA induced activation effect. They also 
support the simplest explanation for the enhanced 
ANCA sensitivity of CD177pos neutrophils, 
namely that the presence of CD177 – likely all of 
which is bound to PR3 – makes a larger 
abundance of ANCA epitopes available than is 
found on CD177neg neutrophils. CD177 likely 
‘presents’ PR3 to the extracellular environment in 
a uniform orientation that maximizes accessibility 
to the most common PR3-ANCA epitopes (7). 
Our results imply that this increase in binding 
sites is sufficient to account for the increased 
ANCA sensitivity of these neutrophils, since 
physically removing them reduces ANCA 
sensitivity to that of CD177neg neutrophils.  
The results do not answer the question of what 
function(s) CD177 actually has in neutrophils and 
why it is found in complex with PR3. They also 
do not rule out entirely that CD177 could 
participate in the ANCA induced activation 
process; the fact that multivalent CD177 binders 
provoke a response similar to that of PR3-ANCA 
provides clues for further studies into the role of 
CD177 in neutrophil biology. The newly 
developed antibodies described here will be of 
great value in analyzing the function of CD177 in 
such experiments and may also be of value in the 
treatment of AAV. Since the removal of CD177-
bound PR3 results in a substantial reduction in 
ANCA-induced neutrophil activation, blocking 
this interaction in vivo could prove beneficial for 
AAV patients, particularly those with large 
CD177pos neutrophil populations. 
 
Experimental Procedures 
Hybridoma generation. Recombinant CD177 was 
prepared as described previously (7) and provided 
to Biogenes GmbH (Berlin) for inoculation of 
mice. Hybridomas delivered by Biogenes were 
cocultured on feeder cells obtained from 
peritoneal lavage of Black6 mice in hybridoma 
medium: Dulbecco’s Minimal Essential Medium 
(DMEM) (Sigma, D5871) supplemented with 
20% fetal calf serum (Merck), 2 mM glutamine 
(Gibco), 1 mM sodium pyruvate (Sigma, S8636) 
and antibiotics (Pen/Strep, Gibco). 
 
IgG isolation and Fab preparation. Stable 
hybridoma cultures were grown in 300 cm2 
culture flasks (TPP) in 50 ml hybridoma medium. 
Cells were split 1:10 every 48 hours (at 80-90% 
confluence) and with complete exchange into 
fresh medium. Collected medium aliquots 
containing IgG were pooled and passed over a 5 
ml Protein G Agarose column (GE Healthcare) 
washed with phosphate buffered saline (PBS, 
Merck) and eluted with 50 mM glycine (Sigma), 
150 mM NaCl (Sigma), pH 3.5 directly into 1 M 
Tris, pH 8.0 for neutralization. Elution fractions 
were pooled and concentrated in 100 kD 
molecular weight cutoff Amicon spin 
concentrators (Millipore). Concentrated IgG were 
further purified over a Superdex 200 size 
exclusion column (GE Healthcare) in 20 mM 
HEPES (Sigma), 150 mM NaCl, pH 7.4. IgG 
containing fractions were verified by SDS-PAGE, 
pooled, concentrated in 30 kD MWCO Amicons 
and stored at 4°C until use.  
Fabs were prepared from purified IgG by 
incubation with Papain-Agarose (Thermo Fisher) 
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according to the manufacturer’s instructions. 
Digested IgG was passed over Protein G agarose 
to remove Fc and undigested IgG and Fab 
containing fractions were pooled, concentrated in 
10 kD MWCO Amicons and subjected to size 
exclusion chromatography as for the IgG.  
 
SPR experiments. Experiments were performed 
on a ProteOn XPR36 instrument (BioRad) using 
standard amine chemistry for coupling IgG to the 
sensor chip (GLH sensor chips, BioRad). Ligand 
dilution series were prepared in ProteOn running 
buffer (PBS supplemented with 0.005% Tween-
20 (Sigma). 
 
Neutrophil preparation. Blood neutrophils from 
healthy human donors were obtained (Ethic 
Votum EA1/277/11) and purified as described 
previously (19). Briefly, neutrophils from healthy 
volunteers were isolated from heparinized whole 
blood by red blood cell sedimentation with 1% 
dextran, followed by Histopaque 1.083 (Sigma) 
density gradient centrifugation, and hypotonic 
erythrocyte lysis. Neutrophils were centrifuged 
and resuspended in HBSS with calcium and 
magnesium (HBSS++, Merck). Cell viability was 
determined by Trypan blue exclusion and 
exceeded 99%. 
 
Separation of CD177pos/mPR3high and 
CD177neg/mPR3low Neutrophil Subsets by 
Magnetic Beads. Neutrophil subsets were 
separated with MACS separation columns 
(Miltenyi Biotec). Isolated neutrophils were 
stained with monoclonal anti-PR3 (clone 43-8-3-
1). MACS rat anti-mouse IgG1 beads were added, 
and cells were pipetted onto a MACS LD column 
and the flowthrough containing the non-labeled 
CD177neg/mPR3low neutrophils was collected. 
Collumns were removed from the magnet to allow 
collection of the labeled CD177pos/mPR3high cells. 
The purity of the two separated subsets was 
assessed by flow cytometry  using a FITC-labeled 
anti-CD177 IgG. 
 
Membrane PR3 Expression on Neutrophils. 
Neutrophils were stimulated with 2 ng/ml TNF 
(30 min., 37 °C, R&D systems) to increase the 
amount of membrane PR3. Cells were washed 
and stained with monoclonal anti-PR3 (clone 81-
3-3)-Alexa488 conjugated IgG (2,5 µg/ml, 20 min. 
on ice). mPR3 expression was assessed by flow  
cytometry using a FACSCalibur istrument. Ten 
thousand events per sample were assayed.  
For blocking experiments, TNF-primed 
neutrophils were incubated with 20 µg/ml anti-
CD177 IgG or Fab (60 min., on ice), The capacity 
to block anti-PR3 IgG binding was tested by 
subsequent incubation with the Alexa488- 
conjugated anti-PR3 IgG. 
 
Measurement of Respiratory Burst. Superoxide 
was measured using the assay of SOD-inhibitable 
reduction of ferricytochrome c. Neutrophils were 
pretreated with 5 ug/ml cytochalasin B for 15 min. 
on ice. Cells (0.75 x 106/ ml) were primed with 2 
ng/ml TNF for 15 min. before stimulating 
antibodies (or Fabs) were added. The final 
concentration was 5 µg/ml for monoclonal 
antibodies or Fabs. 
For superoxide blocking experiments, cells were 
incubated with 20 µg/ml or with indicated 
amounts of anti-CD177 Fab during the TNF 
priming, before the stimulating monoclonal anti-
PR3 (clone 43-8-3-1) or 75 µg/ml purified PR3-
ANCA preparations were added. 
Experiments were performed in 96-well plates at 
37 °C for up to 45 min., and the absorption of 
samples with and without 300 U/ml SOD was 
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Table 1:  
 
                            Blocker? 
 
 









Antibody Affinity ELISA SPR 
7-3-1 8.0 x 10-9M yes yes 
39-5-2 0.14 x 10-9M no no 
40-6-4 3.1 x 10-9M yes yes 
49-3-1 11.9 x 10-9M ~yes no 
72-3-1 9.0 x 10-9M yes yes 
73-8-1 0.92 x 10-9M ~yes no 
80-11-2 2.3 x 10-9M ?? no 
82-2-4 0.76 x 10-9M ~yes no 
90-12-1 1.3 x 10-9M ~yes no 
92-3-4 11.8 x 10-9M ~yes no 
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Figure 1: (A) IgG was immobilized on the SPR sensor chip and subjected to two consecutive 
ligand flows – first with CD177 alone and second with the CD177:PR3 complex. (B) Expected 
sensorgrams for each ligand flow for both blocker and non-blocker IgG; left panel, ligand flow 1; 
right panel, ligand flow 2. (C) SPR sensorgrams showing blocker (labeled in black) and non-
blocker (labeled in red) IgG; Ligand flows 1 and 2 occurred between the horizontal dotted lines. 
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Figure 2: (A) Freshly isolated Neutrophils were incubated with 5 µg/ml anti-CD177 IgG (red line) 
and anti-CD177 Fab (green line) followed by incubation with a FITC conjugated goat anti-mouse 
IgG (Fab specific (Sigma, #F5262) secondary antibody. Isotype staining is shown in grey. Shown 
experiments were perfomed in two sets with two different human blood donors (B) Neutrophils 
were primed with TNFa (2ng/ml) and incubated with non-blocker or blocker anti-CD177 IgG or 
corresponding Fab (20µg/ml), following incubation with anti-PR3-Alexa488 IgG 
(2,5µg/ml).  Histograms show isotype staining (light grey), mPR3 staining (dark grey), and the 
effect of anti-CD177 IgG (red line) and anti-CD177 Fab (green line) on the mPR3 staining 
accordingly. (C) Superoxide generation in neutrophils stimulated with anti-CD177 whole IgG (5 
µg/ml) (dark gray bars) or corresponding Fab (5 µg/ml) (light grey bars). A non-CD177 binding 
isotype was used as negative control (Iso), a commercially available, activating monoclonal IgG 
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Figure 3: (A) Reduced superoxide production in unsorted neutrophils after incubation with 
blocking anti-CD177 Fab. Primed neutrophils were untreated or preincubated with 20 µg/ml 
control Fab (ctrl), blocker Fab (clone 40), or non-blocker Fab (clone 80), followed by 5 µg/ml 
stimulating monoclonal anti-PR3 IgG (dark grey bars), Isotype control (mid grey bars), or without 
.CC-BY-NC-ND 4.0 International licenseavailable under a
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprint (whichthis version posted May 17, 2021. ; https://doi.org/10.1101/2021.05.17.444335doi: bioRxiv preprint 
Reducing surface PR3 reduces PR3-ANCA induced degranulation 
 
 15 
any further stimulation (light grey bars). (left panel, n=5 ). (B) In parallel, mPR3 staining of the 
CD177pos neutrophil subset was assayed after incubation with Fabs as described above. (right panel, 
n=5) (C) Dose–dependent reduction in mPR3 staining on neutrophils after incubation with 
blocking anti-CD177 Fab (clone 40). A representative set of histograms (left panel) and the 
corresponding geometric mean of mPR3 staining of the CD177pos peak (right panel) from all 
experiments are shown. Untreated neutrophils were used as control. Non-CD177 binding control 
Fab (light grey bars), Fab clone 40 (dark grey bars), non-blocking Fab clone 80 (mid grey bars). 
(n=3). (D) Blocker Fab clone 40 negatively influences superoxide generation in neutrophils after 
PR3-ANCA stimulation (75 µg/ml). (n=3) Legend as in (A). Comparison between multiple groups 
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Figure 4: (A) Neutrophils from CD177/mPR3 bimodal donors were separated by magnetic cell 
sorting. Panel shows a representative separation after sorting into CD177pos/mPR3high and 
CD177neg/mPR3low subsets. (B) Blocking of neutrophil activation by anti-CD177 Fab clone 40 is 
restricted to the CD177pos/mPR3high neutrophil subset. As described in Fig. 3A, sorted neutrophils 
(CD177pos/mPR3high, dark grey bars and CD177neg/mPR3low, light grey bars) were assayed for 
superoxide generation. Because a PR3-ANCA epitope could be blocked by the monoclonal PR3 
antibody used for the sorting procedure, polyclonal human PR3-ANCA (75 µg/ml) were used for 
stimulation. (n=3) Comparison between multiple groups were done using ANOVA and 
Bonferroni’s post-hoc test, * indicates p < 0.05 
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